Expertise in
9
conditions

Dr. Leonard J. Seigel

Hematology
Office
4725 N Federal Hwy, 
Fort Lauderdale, FL 
Expertise in
9
conditions
Office
4725 N Federal Hwy, 
Fort Lauderdale, FL 

Overview

Leonard Seigel is a Hematologist practicing medicine in Fort Lauderdale, Florida.

Dr. Seigel is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Anemia, Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), and Richter Syndrome.

He is actively involved in clinical research, participating in 9 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

Office
4725 N Federal Hwy, Fort Lauderdale, FL 33308

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: May 29, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
ARM: Axillary Reverse Mapping - A Prospective Trial to Study Rates of Lymphedema and Regional Recurrence After Sentinel Lymph Node Biopsy and Sentinel Lymph Node Biopsy Followed by Axillary Lymph Node Dissection With and Without Axillary Reverse Mapping
ARM: Axillary Reverse Mapping - A Prospective Trial to Study Rates of Lymphedema and Regional Recurrence After Sentinel Lymph Node Biopsy and Sentinel Lymph Node Biopsy Followed by Axillary Lymph Node Dissection With and Without Axillary Reverse Mapping
Enrollment Status: Active_not_recruiting
Publish Date: April 21, 2026
Intervention Type: Other, Drug, Procedure
Study Drug: Isosulfan Blue
Study Phase: Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
View 8 Less Clinical Trials
Similar Doctors
Expertise in
13
conditions
Dr. Luis E. Raez
Hematology | Oncology
Expertise in
13
conditions
Dr. Luis E. Raez
Hematology | Oncology
Referral may be required

Memorial Cancer Institute

12235 Pines Blvd, 
Pembroke Pines, FL 
 (15.6 miles away)
954-869-5708
Languages Spoken:
English, Portuguese, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Luis Raez is a Hematologist and an Oncologist practicing medicine in Pembroke Pines, Florida. Dr. Raez is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, Lung Adenocarcinoma, and Tissue Biopsy. Dr. Raez is currently accepting new patients.

Expertise in
17
conditions
Expertise in
17
conditions
Referral may be required
1425 Northwest 10th Avenue, Floor 3, 
Miami, FL 
 (28.1 miles away)
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Juan Alderuccio is a Hematologist practicing medicine in Miami, Florida. Dr. Alderuccio is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Marginal Zone Lymphoma (MZL), B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Non-Hodgkin Lymphoma. Dr. Alderuccio is currently accepting new patients.

Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required
1475 Northwest 12th Avenue, Floor 2, 
Miami, FL 
 (28.2 miles away)
305-243-5302
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Justin Watts is a Hematologist practicing medicine in Miami, Florida. Dr. Watts is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Leukemia, Myelofibrosis, and Bone Marrow Aspiration. Dr. Watts is currently accepting new patients.

Frequently Asked Questions about Dr. Leonard J. Seigel

How do I make an appointment with Dr. Leonard J. Seigel?

You can book an appointment with Dr. Leonard J. Seigel by calling their office at 954-267-7700. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Leonard J. Seigel a top-rated expert for Anemia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Leonard J. Seigel is classified as an Advanced expert for Anemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Leonard J. Seigel specialize in?

While Dr. Leonard J. Seigel is a Hematology, they have specific expertise in Anemia, Chronic B-Cell Leukemia (CBCL), and Chronic Lymphocytic Leukemia (CLL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Leonard J. Seigel accept my insurance?

Dr. Leonard J. Seigel accepts most major insurance plans, including Cigna and Humana. We recommend calling the office directly at 954-267-7700 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Seigel's expertise for a condition
ConditionClose
      View All 9 Advanced Conditions
      View All 34 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile